OpenAI acquires biotech startup Orchestra Bio
What you need to know
OpenAI has acquired Orchestra Bio, a four-year-old AI biotech software startup, the company announced on its website. Deal terms were not disclosed. OpenAI says it is adding Orchestra's team and technology to work on Rosalind, its AI model for life sciences research, and on Rosalind Workbench, a tool meant to help researchers plan experiments and analyze results. Orchestra Bio had reportedly raised about $20 million as of 2025 from investors including Andreessen Horowitz, Atria, and 8VC.
Generated by AI from the reporting · updated 30 minutes ago
Timeline
Follow the reports to see every side of the story.
- TechCrunch · AIOpenAI acquires startup Orchestra Bio to beef up its biotech business
OpenAI acquired Orchestra Bio, a four-year-old AI biotech software startup, on Tuesday.
- OpenAI NewsFeaturedOpenAI acquires Orchestra Bio
OpenAI is acquiring Orchestra Bio to bring AI-powered operations to life sciences R&D. The company says the move is meant to help biopharma teams accelerate drug development and advance new treatments.
Heat trend for this story
Not enough continuous data yet to chart a trend.